Skip to main content

Table 3 Changes in outcome parameters after 24 weeks treatment

From: Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes

Variable

The group A (n = 29)

The group B (n = 27)

Baseline

24 weeks

Baseline

24 weeks

Triglyceride (mmol/L)

3.26 ± 1.14

3.16 ± 1.12

3.28 ± 1.16

3.24 ± 1.15

Total Cholesterol (mmol/L)

6.23 ± 1.41

6.18 ± 1.72

6.19 ± 1.51

6.17 ± 1.68

HDL-Cholesterol (mmol/L)

1.04 ± 0.23

1.14 ± 0.38

1.12 ± 0.21

1.13 ± 0.24

LDL-Cholesterol (mmol/L)

4.13 ± 1.01

3.67 ± 1.12

4.20 ± 1.02

3.81 ± 1.20

Serum C peptide (ng/ml)

1.06 ± 0.68

1.18 ± 0.66

1.06 ± 0.70

1.10 ± 0.69

HMW adiponectin (ug/ml)

3.12 ± 1.56

5.86 ± 1.62*

3.22 ± 1.54

3.24 ± 1.53##

  1. Data expressed mean ± SD; LDL: low-density lipoprotein; HMW: high-molecular weight; *p < 0.05 difference compared with baseline, ##p < 0.01 compared absolute changes between the group A and group B following 24 weeks glimepiride treatment.